tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

EDIT Stock Latest News

Editas Medicine initiated with a Buy at JonesResearch
The FlyEditas Medicine initiated with a Buy at JonesResearch
2d ago
EDIT
Editas Medicine to Participate in Upcoming Investor Conferences
PremiumPress Releases
Editas Medicine to Participate in Upcoming Investor Conferences
23d ago
EDIT
Editas Medicine price target lowered to $12 from $20 at Truist
PremiumThe Fly
Editas Medicine price target lowered to $12 from $20 at Truist
1M ago
EDIT
Editas Medicine price target lowered to $7 from $9 at Barclays
PremiumThe Fly
Editas Medicine price target lowered to $7 from $9 at Barclays
1M ago
EDIT
Editas Medicine upgraded to Buy from Neutral at BofA
PremiumThe Fly
Editas Medicine upgraded to Buy from Neutral at BofA
1M ago
EDIT
Editas Medicine reports Q2 EPS (82c), consensus (70c)
PremiumThe FlyEditas Medicine reports Q2 EPS (82c), consensus (70c)
1M ago
EDIT
Editas Medicine Announces Second Quarter 2024 Results and Business Updates
Premium
Press Releases
Editas Medicine Announces Second Quarter 2024 Results and Business Updates
1M ago
EDIT
Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update
Premium
Press Releases
Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update
2M ago
EDIT
Editas Medicine Inc. (EDIT) Q2 Earnings Cheat Sheet
PremiumPre-Earnings
Editas Medicine Inc. (EDIT) Q2 Earnings Cheat Sheet
2M ago
EDIT
Editas Medicine Board Member Resigns, Effective June 2024
PremiumCompany Announcements
Editas Medicine Board Member Resigns, Effective June 2024
3M ago
8K
EDIT
Editas Medicine Reveals Promising Gene Therapy Trial Results
PremiumCompany Announcements
Editas Medicine Reveals Promising Gene Therapy Trial Results
3M ago
8K
EDIT
Editas Medicine announces new safety, efficacy data from EdiTHAL trial
PremiumThe Fly
Editas Medicine announces new safety, efficacy data from EdiTHAL trial
3M ago
EDIT
Editas Medicine announces new safety, efficacy data from RUBY trial
PremiumThe FlyEditas Medicine announces new safety, efficacy data from RUBY trial
3M ago
EDIT
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
Premium
Press Releases
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
3M ago
EDIT
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
Premium
Press Releases
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
3M ago
EDIT
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
PremiumPress Releases
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
4M ago
EDIT
Editas announces preclinical data from in vivo gene editing medicines
PremiumThe Fly
Editas announces preclinical data from in vivo gene editing medicines
4M ago
EDIT
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
PremiumPress Releases
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
4M ago
EDIT
Editas Medicine price target lowered to $15 from $16 at Citi
PremiumThe Fly
Editas Medicine price target lowered to $15 from $16 at Citi
4M ago
EDIT
Editas Medicine price target lowered to $9 from $11 at Barclays
PremiumThe FlyEditas Medicine price target lowered to $9 from $11 at Barclays
4M ago
EDIT
Editas Medicine upgraded to Equal Weight from Underweight at Morgan Stanley
Premium
The Fly
Editas Medicine upgraded to Equal Weight from Underweight at Morgan Stanley
4M ago
EDIT
Editas Medicine reports Q1 EPS (76c), consensus (66c)
Premium
The Fly
Editas Medicine reports Q1 EPS (76c), consensus (66c)
4M ago
EDIT

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >